ANDA 205449, held by Aurobindo Pharma Ltd. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 205449 (Mili), held by Aurobindo Pharma Ltd, was first approved by FDA on Jul 7, 2016, with 3 approved supplements and 0 published complete response letters.
VyLibra is a combination of norgestimate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. 1.1 Oral Contraceptive
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 7, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mili0.035MG;0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Mar 7, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 25, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 7, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters